Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Kiniksa Pharmaceuticals Ltd(KNSA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KNSA
11/13/2026: KNSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Kiniksa Pharmaceuticals is a commercial-stage biotechnology company that has successfully brought ARCALYST to market for niche inflammatory diseases. Its primary strength lies in its focused clinical expertise and established revenue stream from its lead commercial asset. The company's growth story centers on label expansion for ARCALYST and the potential validation of its clinical-stage pipeline. Key risks include heavy dependence on a single product, significant cash burn, and intense competition from large pharmaceutical players. Investors should monitor clinical trial progress and commercial execution, as the stock remains a high-volatility, growth-oriented investment suitable for those comfortable with biotechnology sector risks.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through pipeline maturation but carries high execution risk typical of small-cap biotechs. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find interest during periods of clinical success or revenue acceleration. |
| Value investor | Weak fit | The company is in an investment/growth phase and not currently valued on traditional cash-flow multiples. |
| Dividend investor | Weak fit | Kiniksa does not pay a dividend and is unlikely to do so in the near term. |
| Low-risk investor | Weak fit | High volatility and binary clinical outcomes make this stock unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is sensitive to clinical trial outcomes and commercial adoption rates. |
| Valuation risk | Medium / high | Valuations are highly speculative based on future pipeline success rather than current earnings. |
| Competition risk (immunology) | Medium | Large pharmaceutical companies can outspend Kiniksa in clinical trials and commercial marketing. |
| Business quality | Medium | The company has one primary commercial asset, limiting portfolio diversification. |
| Dividend income | Low / none | The company is in a growth stage and does not offer income. |
| Execution risk | High | Failure to successfully develop or expand the pipeline could materially impact long-term prospects. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.56B USD | Price to earnings Ratio 72.39 | 1Y Target Price 109.43 |
Price to earnings Ratio 72.39 | 1Y Target Price 109.43 | ||
Volume (30-day avg) 821.9K shares | Beta 0.08 | 52 Weeks Range 37.02 - 99.31 | Updated Date 11/12/2026 |
52 Weeks Range 37.02 - 99.31 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.33 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 18.09% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Operations | Sale of ARCALYST for recurrent pericarditis and CAPS. | Revenue is currently derived from a small number of approved therapeutic indications. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-10-27 | When Before Market | Estimate 0.32 | Actual 0.56 |
Profitability
Profit Margin 11.58% | Operating Margin (TTM) 13.79% |
Management Effectiveness
Return on Assets (TTM) 9.62% | Return on Equity (TTM) 17.59% |
Valuation
Trailing PE 72.39 | Forward PE 60.24 | Enterprise Value 6.96B | Price to Sales(TTM) 8 |
Enterprise Value 6.96B | Price to Sales(TTM) 8 | ||
Enterprise Value to Revenue 7.36 | Enterprise Value to EBITDA 52.61 | Shares Outstanding 48.84M | Shares Floating 40.61M |
Shares Outstanding 48.84M | Shares Floating 40.61M | ||
Percent Insiders 3.46 | Percent Institutions 103.12 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.